Today, we've ranked the top biotech penny stocks to watch for September 2017, which includes last month's biggest gainers. Then, we'll show you a biotech stock with future growth potential as high as 94.4% in one year...
| Biotech Penny Stock | Current Share Price (as of Sept. 6) | August 2017 Gain |
| Dimension Therapeutics Inc. (Nasdaq: DMTX) | $3.85 | +142.9% |
| CareDx Inc. (Nasdaq: CDNA) | $2.65 | +115% |
| Tandem Diabetes Care Inc. (Nasdaq: TNDM) | $0.72 | +74.3% |
| Marinus Pharmaceuticals Inc. (Nasdaq: MRNS) | $2.95 | +63.6% |
| Chiasma Inc. (Nasdaq: CHMA) | $2.20 | +63% |
| Tyme Technologies Inc. (Nasdaq: TYME) | $7.44 | +60.8% |
| T2 Biosystems Inc. (Nasdaq: TTOO) | $4.36 | +59.3% |
| MannKind Corp. (Nasdaq: MNKD) | $2.04 | +59.2% |
| Arrowhead Pharmaceuticals Inc. (Nasdaq: ARWR) | $2.97 | +59.1% |
| Oncomed Pharmaceuticals Inc. (Nasdaq: OMED) | $4.62 | +53.4% |
CareDx Inc. (Nasdaq: CDNA) - which makes devices that diagnose changes and complications in organ transplant patients - soared 115% between July 31 and Aug. 31, when the share price jumped from $1.33 to $2.86.
CareDX produces AlloSure, a test that takes a patient's blood sample to see if a transplanted organ rejects the surrounding body tissue. It's conducted right after the procedure to ensure the patient doesn't die from their immune system's negative response to the mismatched organ and tissue.
CDNA was boosted when the firm announced AlloSure will qualify for coverage under Medicare starting Oct. 9. Qualifying for Medicare is a boon for the test, since the American Association of Retired Persons (AARP) says 44 million Americans - or 15% of the U.S. population - are currently enrolled in Medicare.
CDNA shares rallied 38.6% on the day after the announcement, rising from $2.15 to $2.98 over Aug. 24-25.
CDNA will be a biotech penny stock to watch both in September, leading up to AlloSure's Medicare debut, and in October, once it becomes available to Medicare patients.
BREAKING: New Legislation Could Turn Tiny Pot Stocks into Millions. Click Here...
But the top gainer on our biotech penny stocks list is Dimension Therapeutics Inc. (Nasdaq: DMTX). Shares of this company - which develops medicines for people with rare, inherited disorders like hemophilia - gained 142.9% last month, rising from $1.40 to $3.40.
The stock rocketed 162.5% on Aug. 25 alone after small-cap firm Regenxbio Inc. (Nasdaq: RGNX) said it will acquire Dimension for $86 million. That meant Regenxbio offered $3.41 per share for DMTX - a 184.2% premium - even though the stock was only trading at $1.20 a share. Regenxbio's offer sent DMTX above $3 per share for the first time since Jan. 30.
Despite triple-digit gains for the two stocks, we're not recommending CDNA or DMTX as "buys" today. In fact, we don't advise buying any of the firms on our top penny stocks list. We're interested in finding stocks that are set for future returns, not stocks that already peaked a month ago.
That's where Money Morning Executive Editor Bill Patalon comes in. Today, he's going to show you one of the best biotech stocks to invest in right now...
Bill boasts over 10 years of experience handpicking the best stocks to buy for our Money Morning Members. One of his recommendations has surged 510.5% since he first told readers about it on April 9, 2012. Those returns have crushed the S&P 500's 75.6% gain over the same period.
Shares of today's pick cost just under $10 each. While that's more expensive than the penny stocks on our list, this pick is still affordable and worth the few extra bucks.
Not only is Bill bullish on this biotech stock, but analysts are as well. Analysts from Thomson Reuters predict shares of this stock could rally as much as 94.4% through September 2018. That means you could nearly double your initial investment if you buy in today.
Here's Bill's recommendation...
The Best Biotech Stock to Buy for a 94.4% Return in One Year
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
One of Bill's favorite stocks right now is Insys Therapeutics Inc. (Nasdaq: INSY), a company that develops cancer-related medicines and treatments. One of its products is Subsys, an opioid spray used to treat cancer pain.
But its newest drug, Syndros, is one of the biggest reasons Bill likes INSY stock. Available for doctors to prescribe as of July 31, Syndros treats chemotherapy-induced nausea and vomiting (CINV), which affects 70-80% of the more than 15 million cancer patients in the United States.
The drug also treats anorexia stemming from weight loss in AIDS patients. According to data from the U.S. Centers for Disease Control and Prevention (CDC), there are 1.1 million U.S. citizens living with AIDS.
Sales of medicines that treat pain are expected to soar over the next seven years. Transparency Market Research says revenue from the pain treatment industry could rise to $83 billion in 2024 - up 38.3% from $60 billion two years ago.
And Syndros has another advantage over other drugs in the pain management market.
Subsys is an opioid-based product, but Bill says Syndros will boost INSY stock because it works without using opioids. With opioid addiction becoming a national epidemic - opioid-related deaths increased by over 25% last year alone - doctors and patients are looking for non-opioid pain treatment as a way to avoid addiction.
Syndros is a safe substitute for opioid-based medicines because its main ingredient is a form of Delta-9-THC, which naturally occurs in marijuana. According to Bill, Syndros's presence in both the growing medical marijuana industry - where sales are expected to grow by 183% through 2020 - and the non-opioid pain relief market make INSY stock the perfect "war on pain" play.
"Insys has big upside because it's trying (and, so far, succeeding with flying colors) to work at the 'convergence' of those two powerful trends," Bill said on May 30.
Analysts are also bullish on INSY stock. Thomson Reuters analysts give it a high one-year price target of $18 per share. That means you could see a return of 94.4% - nearly doubling your money - if you purchase shares at today's price of $9.26.
Up Next: "Chemotherapy Will Become Obsolete"
The FDA has approved a new medical device. It's spreading rapidly to hospitals not only in all 50 states, but also to every country in Europe.
It's revolutionizing the treatment of nearly every form of cancer.
That's why analysts project its sales to spike 63,000% and create $7 trillion in new wealth.
Follow Money Morning on Twitter @moneymorning, Facebook, and LinkedIn.